Global Breast Cancer Monoclonal Antibodies Market

The antibody-drug conjugates (ADCs) market consists of sales of antibody-drug conjugates. ADCs are complex engineered therapeutics consisting of monoclonal antibodies, directed toward tumor-associated antigens, to which highly potent cytotoxic agents are attached using chemical linkers. The antibody drug conjugates market covered in this report is segmented by type into monoclonal antibodies, linker, drug/toxin, others. The antibody-drug conjugates (ADCs) market is also segmented by application into blood cancer, breast cancer, ovarian cancer, lung cancer, brain tumor, others; by product into adcertis, kadcyla, others; by technology into immunogen technology, seattle genetics technology, immunomedics technology, others; by end user into hospital, clinics, others. The global antibody drug conjugates market is expected to grow from $2.34 billion in 2020 to $2.6 billion in 2021 at a compound annual growth rate (CAGR) of 11.1%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The antibody-drug conjugates (ADCs) market is expected to reach $6.12 billion in 2025 at a CAGR of 23.9%. The antibody drug conjugates market is being driven by rising incidences of cancer globally. The major causes for most cancers include obesity, smoking, alcohol, improper eating habits. The Cancer Research UK predicts that there will be 27.5 million new cases of cancer each year by 2040. The rising incidences of cancer are expected to increase the demand for antibody drug conjugates driving market growth. The challenges involved in the manufacturing of ADC's is acting as a restraint on the antibody drug conjugates market. ADC manufacturing facilities require high capital investment and extensive specialized training for operators. ADC process development is complicated as it requires optimization of additional process steps that are not present in conventional monoclonal antibodies manufacturing such as the antibody-drug conjugation reaction and subsequent drug substance purification. Also, antibody drug conjugates must be manufactured in aseptic environments and operating personnel should be protected from the highly toxic drug compounds, thereby presenting operational difficulties. Manufacturers of antibody drug conjugates are increasingly collaborating or partnering with other companies to share technology, resources, product knowledge and expand business. For instance, in March 2019, Astrazeneca entered into a global development and commercialization collaboration agreement with Daiichi Sankyo Company for the proprietary antibody drug conjugate trastuzumab deruxtecan (DS-8201). In April 2019, Shanghai Miracogen entered into an agreement with Netherlands based Synaffix to use its tools for building antibody drug conjugates. According to the deal, Miracogen is licensing two platforms from Synaffix which is expected to boost its product pipeline. Manufacturers of antibody drug conjugates are monitored by various regulatory bodies such as the Food and Drug Administration in the USA. In the USA, there is no specific regulatory guidance to industry on ADC development and the FDA follows existing guidelines for small drugs and monoclonal antibodies to regulate ADC. The product quality offices at FDA such as the Office of Biotechnology Products (OBP)/Office of Pharmaceutical Quality primarily focus on the manufacturing of the antibody component of the ADC and the control strategy for the antibody intermediate, as well as for the drug substance (DS) and drug product (DP). Small molecule review groups in the Office of Pharmaceutical Quality bear primary responsibility for review of the adequacy of the payload and linker, conjugation reaction and aspects of the control strategy. Major players in the antibody-drug conjugates (ADCs) market are Bayer AG, Concortis Biotherapeutics, F. Hoffman-La Roche Ltd., Immunomedics Inc., and Oxford BioTherapeutics. The regions covered in the antibody-drug conjugates (ADCs) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the antibody-drug conjugates (ADCs) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global antibody drug conjugates market is segmented - 1) By Type: Monoclonal Antibodies, Linker, Drug/Toxin, Others 2) By Application: Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumor, Others 3) By Product: Adcertis, Kadcyla, Others 4) By Technology: Immunogen Technology, Seattle Genetics Technology, Immunomedics Technology, Others 5) By End User: Hospital, Clinics, Others

The drugs for hormonal replacement therapy market consists of sales of drugs for hormonal replacement therapy and related services. The drugs for hormonal replacement therapy are used to treat patients with growth hormone deficiency caused due to conditions such as dwarfism or menopause (a condition which describes changes a woman goes through when her menstruating cycle stops). The drugs for hormonal replacement therapy help to replace low level hormones from the body, maintain growth hormone deficiency and prevent women from vaginal dryness, mood swings, weakening of bones and others. The market covered in the drugs for hormonal replacement therapy market report is segmented by therapy type into estrogen replacement therapy, human growth hormone (HGH) replacement therapy, thyroid replacement therapy, testosterone replacement therapy; by distribution channel into hospital pharmacies, retail pharmacies, online pharmacies; by application into hypothyroidism, male hypogonadism, growth hormone deficiency, menopause, others; by route of administration into oral, parental, others. The global drugs for hormonal replacement therapy market is expected to grow from $14.76 billion in 2020 to $14.88 billion in 2021 at a compound annual growth rate (CAGR) of 0.8%. The slow growth is mainly due to defering treatments that led to fall in the demand for drugs. The drugs for hormonal replacement therapy market is expected to reach $16.77 billion in 2025 at a CAGR of 3%. Increasing population of aging and postmenopausal women is driving the drugs for hormonal replacement therapy market growth. Hormonal replacement therapy drugs such as Estrogen, Progestin and others are used to treat medical conditions caused due to menopausal conditions. According to a report by The Indian Menopause Society, New Delhi, in India there are 65 million women over the menopausal age affected with menopausal symptoms. According to European Menopause and Andropause Society (EMAS) report, women aged over 60 are expected to reach over 1 billion by 2050. In South Korea, the female population is expected to exceed male population by 2060, out of which 59.6% of female population is expected to suffer from postmenopausal symptoms. Thus, growing women population suffering from menopausal symptoms and aging population drives the market for hormonal replacement therapy drugs market. Increasing occurrence of side effects due to the intake of drugs for hormonal deficiency may hinder growth of drugs for hormonal replacement therapy market. The side effects include vagina dryness, irregular heartbeat, breast swelling, osteoporosis (weakening of bones) and other effects when women undergo hormonal replacement therapy. High dosage of drugs for hormonal replacement therapy may cause rapid heartbeat, bloating (a build-up of gas in the stomach and intestines), nausea, indigestion, vaginal bleeding, blood clots, heart attack, breast cancer and others. According to an online study, decrease in the intake of drugs for combined hormone therapy showed a decrease in breast cancer cases by 126,000 and cardiovascular disease cases by 76,000. Thus, the increasing side effects of drugs hinders the growth of drugs for hormonal replacement therapy. Companies in the industry are increasingly developing of drugs for hormonal replacement therapy with better safety profiles and novel drug delivery mechanisms. The drug delivery mechanisms include transdermal estrogen, varginal estrogen and others. Transdermal estrogen drug delivery is in the form of estradiol transdermal gel, patch, and spray that are used to treat symptoms of menopause, vaginal dryness, itching, burning and others occur due to low estrogen levels. Varginal estrogen in the form of cream, vaginal ring, vaginal tablets are used to get the hormone estrogen into the system. For instance, Novo Nordisk, a multinational pharmaceutical company provides novel drug delivery mechanisms and low dose drugs for hormonal replacement therapy (HRT) to cater to the rising demand of patient needs. Some of the brands offering of novel drugs include Climara, Divigel, Elestrin, Esclim, Estraderm, Estrasorb, EstroGel, Evamist, Oesclim, Rhoxal-Estradiol Derm 50, Vivelle 100 Mcg, Estradot Transdermal Therapeutic System and others. Department Of Health And Human Services of Food And Drug Administration (FDA), a federal agency, is a regulatory body monitoring, controlling and regulating the drugs for hormonal replacement therapy market. In April 2018, FDA's Department Of Health And Human Services has revised the requirements of specific hormone-containing drug products for human use. These hormones include estrogens, progestins, androgens, anabolic steroids, adrenal corticosteroids, and synthetic analogs. The purpose of the revisal of existing regulations by FDA is to establish effectiveness and ensure safety for any over-the-counter drug use of these ingredients. Major players in the drugs for hormonal replacement therapy market are Novartis AG, Bayer AG, Pfizer Inc., Novo Nordisk A/S, and Eli Lilly and Company. The regions covered in the drugs for hormonal replacement therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the drugs for hormonal replacement therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global drugs for hormonal replacement therapy market is segmented - 1) By Therapy Type: Estrogen Replacement Therapy, Human Growth Hormone (HGH) Replacement Therapy, Thyroid Replacement Therapy, Testosterone Replacement Therapy 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 3) By Application: Hypothyroidism, Male Hypogonadism, Growth Hormone Deficiency, Menopause, Others 4) By Route of Administration: Oral, Parental, Others

The HER2 inhibitors market consists of sales of HER2 inhibitors and related services by entities (organizations, sole traders, and partnerships) that manufacture HER2 inhibitors. Human epidermal growth factor receptor (HER2) inhibitors slow down or stop cell growth thus reducing the risk for cancer growth. The HER2 inhibitor market covered in this report is segmented by treatment into monotherapy, combination therapy; by application into squamous cell carcinoma, adenocarcinoma, large cell carcinoma, breast cancer, others; by end user into hospitals, clinics, others. The global her2 inhibitors market is expected to grow from $5.98 billion in 2020 to $6.4 billion in 2021 at a compound annual growth rate (CAGR) of 7%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The HER2 inhibitors market is expected to reach $9.31 billion in 2025 at a CAGR of 10%. The rise in the number of breast cancer cases across the globe is likely to contribute to the growth of the HER-2 inhibitors market during the forecast period. According to the American Cancer Society, there were 1.7 million new cases and 0.6 million cancer deaths in 2019 in the USA. As of January 2020, there were more than 3.5 million women with a history of breast cancer in the US. This includes women currently being treated and women who have completed their treatment. According to the World Health Organization (WHO), 627,000 people died of breast cancer in 2018, which is about 15% of all women cancer deaths. Therefore, the rise in the breast cancer incidence rate globally is anticipated to boost the demand for the HER-2 inhibitors market over the forthcoming years. High costs associated with the HER-2 inhibitors treatment is a major issue faced by citizens of many countries. The pressure to contain costs and demonstrate value is widespread. Political uncertainty and persistent economic stress in numerous countries are calling into question the sustainability of public health care funding. In less wealthy countries, the lack of cost-effective therapies for cancer has influenced the health conditions of the population and has led to a low average life expectancy. Trastuzumab, a licensed HER2 inhibitor, has been the most expensive systemic cancer therapy procedure at a variety of disease sites. In 2019, the cost of trastuzumab in India ranged from $774.6 to $841.35 per 440 mg vial. In patients with HER 2 positive early breast cancer, nearly 18 cycles of therapy based on trastuzumab are needed that further charge more than $1,335.52 in India. Therefore, the high cost of HER2 inhibitors is expected to hinder the growth of the HER2 inhibitors market. Biotechnology companies are focusing on acquiring or partnering with biopharmaceutical companies to develop and promote the HER-2 inhibitors market. There have been several partnerships in recent years which help these companies to increase their HER-2 inhibitors portfolio, enhance their revenues and share the costs. For instance, in June 2020, Alphamab Oncology, a biotechnology company, collaborated with Sanofi, a pharmaceutical company, for investigating KN026 in combination with other drugs for the treatment of HER2 breast cancer. KN026 is a HER2 inhibitor developed by Alphamab Oncology. In 2019, Daiichi Sankyo announced its collaboration with AstraZeneca for development and commercialization collaboration for Daiichi Sankyo’s HER2 targeting antibody drug conjugate. In March 2018, Seattle Genetics announced its decision to acquire Cascadian Therapeutics for $614 million. The acquisition is expected to positively impact Seattle Genetic's product portfolio and boost its late-stage cancer drug pipeline. Cascadian Therapeutics is a US-based company that had developed an oral tyrosine kinase inhibitor, which is pivotal in mid-stage tests for advanced HER2 breast cancers. It is also slated for tests in other HER2 cancers such as colon cancer. Major players in the HER2 inhibitors market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Pfizer Inc., Puma Biotechnology Inc., Boehringer-Ingelheim, Mylan, Biocon. The regions covered in the HER2 inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the HER2 inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global HER2 inhibitors market is segmented - 1) By Treatment: Monotherapy, Combination Therapy 2) By Application: Squamous Cell Carcinoma, Adenocarcinoma, Large Cell Carcinoma, Breast Cancer, Others 3) By End User: Hospitals, Clinics, Others

The cancer monoclonal antibodies market consists of sales of monoclonal antibodies used for the treatment of cancer and related services by entities (organizations, sole traders and partnerships) that produce monoclonal antibodies for cancer treatment. Monoclonal antibodies are highly specific molecules for cancer cells as they bind to the proteins on their surface and it activates an immune response. The market consists of revenue generated by cancer monoclonal antibodies companies manufacturing cancer monoclonal antibodies drugs. The cancer monoclonal antibodies market covered in this report is segmented by monoclonal antibody therapies into bevacizumab (avastin), rituximab (rituxan), trastuzumab (herceptin), cetuximab (erbitux), panitumumab (vectibix), others and by application into breast cancer, blood cancer, liver cancer, brain cancer, colorectal cancer, others. The global cancer monoclonal antibodies market is expected to grow from $45.51 billion in 2020 to $49.77 billion in 2021 at a compound annual growth rate (CAGR) of 9.4%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The cancer monoclonal antibodies market is expected to reach $69.96 billion in 2025 at a CAGR of 9%. The rise in the number of cancer cases across the globe is likely to contribute to the growth of the cancer monoclonal antibodies market. According to the American Cancer Society, there were 1.7 million new cases and 0.6 million cancer deaths in 2019 in the USA. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43% of all new cancer cases. Therefore, the rise in cancer incidence rate globally is anticipated to boost the demand for the cancer monoclonal antibodies market. The high costs involved in the development of monoclonal antibodies with advanced techniques act as a major restrain for the market due to the complex production process, expensive biological and chemical materials, and clinical trials, as well as required safety, efficacy, and quality tests. Advanced equipment is required for the large-scale production of monoclonal antibodies that encompass multiple disulfide bonds and post-translational modifications, and this equipment is expensive. Clinical efficacy is usually achieved by injecting large amounts of monoclonal antibodies into the system, which means that large quantities are required to be produced for each treatment, thus increasing the cost. According to The American Journal of Managed Care, the annual price of monoclonal antibody therapies used in oncology and hematology is about $100,000 higher than those used in other disease states. Thus, the high development costs in using these advanced techniques will restrain market growth. Companies in the cancer monoclonal antibodies market are increasing their product innovation through strategic collaborations. To sustain in the increasingly competitive market, companies are developing innovative products as well as sharing skills and expertise with other companies. While companies have long collaborated with each other as well as academic and research institutions in this market by way of partnerships and in- or out-licensing deals, this trend has been increasing over recent years. For instance, in September 2020, AbbVie and I-Mab entered into a strategic partnership for the development and commercialization of lemzoparlimab (also known as TJC4), which is a monoclonal antibody drug used to treat multiple cancers. In September 2019, IRBM announced the signing of a service and development agreement with The University of Texas MD Anderson Cancer Center. The agreement will focus on the development of therapeutic monoclonal antibodies for cancer. In March 2020, Gilead Sciences, a US-based biopharmaceutical company, announced its decision to acquire Forty Seven for $4.9 billion. This acquisition is expected to strengthen Gilead’s immuno-oncology R&D portfolio with the addition of Forty Seven’s investigational lead product candidate, magrolimab. Magrolimab is a monoclonal antibody in clinical development for the treatment of several cancers. Forty Seven Inc. is a clinical-stage immuno-oncology company that develops therapies targeting cancer immune evasion pathways and specific cell targeting approaches based on technology licensed from Stanford University. Major players in the cancer monoclonal antibodies market are Amgen, Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Genmab AS, GlaxoSmithKline, Johnson & Johnson, Novartis AG, Merck & Co., and Spectrum Pharmaceuticals. The regions covered in the cancer monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cancer monoclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global cancer monoclonal antibodies market is segmented - 1) By Monoclonal Antibody Therapies: Bevacizumab (Avastin), Rituximab (Rituxan), Trastuzumab (Herceptin), Cetuximab (Erbitux), Panitumumab (Vectibix), Others 2) By Application: Breast Cancer, Blood Cancer, Liver Cancer, Brain Cancer, Colorectal Cancer, Others 3) By End User: Hospitals And Clinics, Research Laboratories, Pharmacies, Others

The breast imaging devices market consists of sales of breast imaging devices and related services by entities (organizations, sole traders, and partnerships) that manufacture breast imaging devices. Breast imaging devices are medical devices used in the diagnosis of medical conditions related to the breast. Some of the breast imaging processes include mammography, MRI, and ultrasound. The global breast imaging devices market is expected to grow from $3.461 billion in 2020 to $3.754 billion in 2021 at a compound annual growth rate (CAGR) of 8.5%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $6.091 billion in 2025 at a CAGR of 13%. The rising prevalence of breast cancer is anticipated to contribute to the breast imaging devices market’s growth. A growing number of hormone replacement therapy (HRT), hormonal imbalances, menopause, and various reproductive disorders have significantly increased the risks of breast cancer. According to the World Health Organization (WHO), breast cancer is the most common cancer in women, impacting 2.1 million women annually. Breast cancer causes the highest number of cancer-related deaths among women. In 2018, approximately 627,000 women died from cancer, which is about 15% of all cancer deaths across the globe. Thereby, the increasing prevalence of breast cancer is expected to boost the demand for detection and diagnosis equipment including breast imaging devices over the forthcoming years. High cost associated with breast imaging devices is expected to limit the growth of the market in the near future. The cost of digital mammography systems varies for different models and companies. For instance, the cost of the 2D model’s mammography systems ranges between $65,000 to $95,000 for GE Healthcare and Hologic, Inc products. Whereas 3D models of the same company’s range between $90,000 to $200,000. In addition to this, the premium 3D models of GE Healthcare and Hologic Inc. are priced between $1,40,000 to $2,75,000. Therefore, the high cost of breast imaging systems is a major concern for end-users, which is predicted to hinder the growth of breast imaging devices market over the forecast period. Major players operating in breast imaging devices market are undertaking various strategic initiatives such as the launch of technologically advanced or innovative products and product portfolio expansion, which is likely to be a leading trend in the breast imaging market. Various companies are introducing new advanced devices in the market to attract a large customer base and maintain their position in the competitive business environment. For instance, in October 2018, GE Healthcare, a USA-based company engaged in manufacturing and sales of diagnostic imaging agents and radiopharmaceuticals used in medical imaging procedures, launched the Invenia Automated Breast Ultrasound (ABUS) 2.0 in the USA. The device is an ultrasound supplemental breast screening technology designed particularly for detecting cancer in dense breast tissue. Moreover, in July 2018, Hologic, Inc., a USA-based medical technology company, introduced Viera portable breast ultrasound system, a handheld device that delivers high-quality imaging to perform guided interventions in the USA and Europe. In June 2019, Hologic, Inc., a USA-based innovative medical technology company focused on improving women's health and well-being through early treatment and diagnosis, announced the acquisition of SuperSonic Imagine for an amount of $85 million. With the acquisition of SuperSonic Imagine, Hologic, Inc. aims to gain entry in cart-based breast ultrasound technology used to screen women with dense breast tissue. SuperSonic Imagine is a France-based company specialized in ultrasound medical imaging including breast imaging devices. The major players covered in the global breast imaging devices market are Siemens Healthcare, GE Healthcare, Dilon Technologies Inc., Hologic Inc, Gamma Medica Inc, Fujifilm Holdings Corporation, SonoCine Inc, Philips Healthcare, Toshiba Corporation, Aurora Imaging Technology Inc., Canon Inc., Dilon Technologies Inc, Delphinus Medical Technologies, Planmed Oy, Micrima Limited, CMR Naviscan Corporation, SuperSonic Imagine, Carestream Health, Samsung Medison Co. Ltd. The countries covered in the global breast imaging devices market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The regions covered in the global breast imaging devices market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The global breast imaging devices market is segmented - 1) By Product Type: Tomosynthesis, Breast Ultrasound, Breast MRI, Mammography, Nuclear Imaging, Others 2) By Technology: Ionizing, Non Ionizing 3) By End User: Hospitals & Clinics, Breast Care Centers, Diagnostic Imaging Centers

The breast cancer drugs market consists of sales of breast cancer drugs and related services. This industry includes establishments that produce drugs used in chemotherapy, surgery and radio therapy for treating breast cancer. The global breast cancer drugs market is expected to grow from $14.25 billion in 2020 to $14.82 billion in 2021 at a compound annual growth rate (CAGR) of 4%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $19.49 billion in 2025 at a CAGR of 7.1%. The increasing prevalence of breast cancer is driving the breast cancer drugs market. Breast cancer is the most common type of cancer among women and affects around 2.1 million women each year. According to the World Health Organization, in 2018, an estimated 627,000 women died from breast cancer, accounting for 15% of all cancer related deaths among women. The factors responsible for breast cancer include heredity, age, lifestyle of a person and is more common in developed countries. As the number of people diagnosed with breast cancer rises, the demand for breast cancer drugs increases, thereby driving market growth. Adverse side effects caused by the use of breast cancer drugs is acting as a restraint on the breast cancer drugs market. Breast cancer drugs can result in long term or short term side effects including headaches, dental issues, osteoporosis, heart problems, cataracts, blood clots, infertility and others. As a result, patients depend on alternate or complementary treatments to deal with the side effects, thereby increasing overall treatment costs. Also, the long lasting nature of some of the side effects discourage the use of breast cancer drugs, affecting market growth. Manufacturers of breast cancer drugs are increasingly collaborating or partnering with other companies to share technology, resources, product knowledge and expand business. For instance, in March 2019, Astrazeneca entered into a partnership deal worth $6.9 billion for the development of a breast cancer drug. According to the deal, the companies will jointly develop the drug trastuzumab deruxtecan and will share development and commercialization costs for the drug worldwide. Novartis collaborated with IBM Watson Health for the development of a solution that can determine drug combinations and sequences for best patient outcomes. Manufacturers of breast cancer drugs are governed by various regulatory bodies such as the Food and Drug Administration in the USA and the European Medicines Agency in the European Union. The European medicinces agency (EMA) regulates the market for breast cancer drugs by granting licences to the drugs that have been proven to be safe and clinically effective. The drug is evaluated to understand its benefits and risks and then tested for any post usage effects. The drug can be commercially sold in the European Union upon approval from the EMA. The EMA can also grant a “conditional marketing authorisation" indicating approval, but can withdraw it if found unsafe or ineffective. Major players in the market are F. Hoffmann-La Roche Ltd, Novartis AG, AstraZeneca, Eli Lilly and Company, Celgene Corporation. The countries covered in the global breast cancer drugs market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA, Australia. The regions covered in the global breast cancer drugs market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The global breast cancer drugs market is segmented - 1) By Drug Type: HER2 Inhibitors, Mitotic Inhibitors, Anti-metabolites, Aromatase Inhibitors, Hormonal Receptor 2) By End User: Hospitals, Clinics, Others 3) By Sales Channel: Ambulatory Surgical Centres, Hospitals, Clinics, Retail Pharmacies, Online Channels

The breast cancer diagnostics market consists of sales of breast cancer diagnostic devices and related services by entities (organizations, sole traders and partnerships) that produce breast cancer diagnostics devices. These devices are used to diagnose breast cancer. Only goods and services traded between entities or sold to end consumers are included. The global breast cancer diagnostics market is expected to grow from $4.621 billion in 2020 to $5.466 billion in 2021 at a compound annual growth rate (CAGR) of 18.3%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $7.458 billion in 2025 at a CAGR of 8%. The increasing incidence of breast cancer will require more equipment to diagnose, which will further increase the demand for breast cancer diagnostics market. Breast cancer is the most common form of cancer, affecting 2.1 million women every year, and furthermore causing the largest number of deaths from cancer in women. The goal of the early diagnosis is to improve the percentage of breast cancers diagnosed at an initial point so that more successful care will be used and the risk of death from breast cancer can be reduced. According to the World Health Organization (WHO), 627,000 people died of breast cancer in 2018, which is about 15% of all cancer deaths in women. Therefore, the increasing incidence of breast cancer is expected to drive the growth of the breast cancer diagnostics market. The high cost of diagnosis of breast cancer is a key factor that hinders the growth of the market for diagnostics of breast cancer. The cost of diagnosis for breast cancer typically rose with the initiation of the diagnostic stage of the disease. According to a 2019 study conducted by Mesothelioma Center, around 63% of respondents that comprise of people with cancer and their family members reported financial difficulties. For instance, the total cost of diagnosis for breast cancer was $353 per patient but diagnostic costs varied from $151 in some regions to $751 in others. Therefore, the high-cost diagnosis of breast cancer makes the process a distant option and hinders the growth of the breast cancer diagnostics market. The technological advancement is a key trend in the breast cancer diagnostics market. Several new techniques have been developed which could be used in the diagnosis and treatment of breast cancer. The 3D mammography, also known as breast tomosynthesis, takes photographs around the breast from various angles and translates them into a 3-D model. In March 2019, Southwest Medical Center, a US-based company, launched 3D mammography services that provide patients with access to enhanced breast imaging services closer to home. In November 2019, EXACT Sciences Corporation, a US-based molecular diagnostics company, acquired Genomic Health for $2.8 billion. Through this acquisition, Exact Sciences will be able to facilitate therapy decisions for colorectal, breast and prostate cancers by Genomic Health’s Oncotype DX gene expression. Genomic Health is a US-based genomic diagnostics manufacturer. The major players covered in the global breast cancer diagnostics market are Abbott Laboratories, Myriad Genetics Inc, Hologic Inc, Koninklijke Philips N.V., Fujifilm Holdings Corporation, GE Healthcare, Thermo Fischer Scientific Inc, Siemens AG, NanoString Technologies Inc, C. R. Bard Inc, Gamma Medica Inc, Aurora Imaging Technology Inc, Dilion Technologies Inc, Genomic Health, F. Hoffmann-La Roche Ltd, Micrima Limited, Provista Diagnostics Inc, Leica Biosystems Nussloch GmbH, bioTheranostics Inc, Bio-Rad Laboratories Inc, Illumina Inc, Biocept Inc, Epigenomics AG, AstraZeneca plc, Quest Diagnostics Incorporated. The countries covered in the global breast cancer diagnostics market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The regions covered in the global breast cancer diagnostics market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The global breast cancer diagnostics market is segmented - 1) By Type: Imaging, Biopsy, Genomic Tests, Blood Tests, Others 2) By Technology: Fluorescent In Situ Hybridization (FISH), Comparative Genomic Hybridization (CGH), Immunohistochemical (IHC), Other Technologies 3) By Cancer Type: BRCA Breast Cancer, ER & PR Breast Cancer, HER 2 Breast Cancer, EGFR Mutation Test Breast Cancer, Others 4) By Diagnostic Type: Ionizing Breast Imaging Technologies, Non-ionizing Imaging Technologies 5) By End Users: Hospitals and Clinics, Cancer Research Centers, Diagnostic Laboratories, Ambulatory Surgical Centers

The laryngoscope market consists of sales of laryngoscopes and related services by entities (organizations, sole traders and partnerships) that manufacture laryngoscopes. A laryngoscope is a medical device used to view and examine the larynx and vocal cords in the throat. This device is also used during tracheal intubation in patients requiring ventilator support. Only goods and services traded between entities or sold to end consumers are included. The global laryngoscope market is expected to grow from $0.132 billion in 2020 to $0.136 billion in 2021 at a compound annual growth rate (CAGR) of 3%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $0.164 billion in 2025 at a CAGR of 5%. The growing prevalence of laryngeal cancers, infections and chronic respiratory diseases is one of the key reasons expected to boost laryngoscope market growth. Laryngeal cancer is a head and neck cancer that occurs when abnormal (malignant) cells form in the larynx. In 2018, there were 81,806 male deaths and 12,965 female deaths worldwide from larynx cancer. Moreover, in 2020, in the United States, there were 12,370 new cases and 3,750 deaths from laryngeal cancer. Therefore, the increasing prevalence of laryngeal cancer increased the demand for laryngoscope and thereby contributed to market growth. Soft tissue injury caused by a laryngoscope is a restraining factor for the laryngoscope market. The most common complication is an injury to the soft palate, although injuries also occur to the teeth, larynx, tongue, and retromolar trigone. The oropharynx is specifically at risk of injury because the video laryngoscope causes the tonsillar pillars to elevate and stretch anteriorly, making them more prone to injury as the tube is being advanced. The soft tissue damage in traditional laryngoscopy is caused mainly by insertion of the laryngoscope, but soft tissue injury with the video laryngoscope is caused by insertion of the endotracheal tube (ETT) itself, as it is often designed blindly into and through the oral cavity and pharynx until it is finally in view at the video laryngoscope monitor. The complications caused demand for a better device, restraining the laryngoscope market. Robot-assisted laryngoscopy is one of the key trends shaping the laryngoscope market. Growing complications or risks associated with advanced and experimental procedures contribute to increased demand for robot-assisted laryngoscopy. The characteristics of robot-assisted devices such as reliability will increase precision levels and have near-absolute geometric accuracy, which helps to reduce the workload of the specialists and improve patient care. Implementing robotic systems leads to faster skill development than manual procedures, and also improves performance and safety. Johns Hopkins University developed a robotic tool to improve surgeons' access to the larynx (voice box). The experts are designing a robotic laryngoscope that can be used with one hand like a joystick. In January 2018, Dilon Technologies, a global leader in designing, manufacturing, and commercializing innovative medical imaging solutions, acquired the CoPilot VL video laryngoscope for an undisclosed amount. This acquisition will help Dilon Technologies expand its footprint into the anesthesia and airway field. CoPilot VL joins Dilon's growing range of imaging and intraoperative devices, including its Molecular Breast Imaging Program for breast cancer diagnosis and the Dilon Navigator Gamma Cancer Surgery Probe. The major players covered in the global laryngoscope market are Ambu, Hill-Rom Holdings, Inc., KARL STORZ, Medtronic, Olympus, HOYA, Roper Technologies, Inc. (Verathon, Inc.), Richard Wolf GmbH, Schoelly Fiberoptic GmbH, Welch Allyn Inc, Timesco Healthcare Ltd, GIMMI GmbH, Zhejiang Tiansong Medical Instrument, XION GmbH, HEINE OPTOTECHNIK GmbH & Co. KG, Truphatek International Ltd, Kangji Medical, Shenda Endoscope, Rudolf Riester GmbH. The countries covered in the global laryngoscope market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The regions covered in the global laryngoscope market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The global laryngoscope market is segmented - 1) By Type: Indirect Laryngoscope, Direct Laryngoscope 2) By Product: Video Laryngoscopes, Standard Laryngoscopes, Fiber-optic Laryngoscopes 3) By End-User: Hospitals, Clinics, Medical Examination Center